Instability of bacteriophages in spray-dried trehalose powders is caused by crystallization of the matrix

[Display omitted] Spray drying is a valuable technique in pharmaceutical dosage formulation, capable of producing amorphous, spherical powders, suitable for pulmonary deposition and further downstream processing. In this study, we show that spray drying bacteriophages together with trehalose results...

Full description

Saved in:
Bibliographic Details
Published inInternational journal of pharmaceutics Vol. 472; no. 1-2; pp. 202 - 205
Main Authors Vandenheuvel, Dieter, Meeus, Joke, Lavigne, Rob, Van den Mooter, Guy
Format Journal Article
LanguageEnglish
Published Netherlands Elsevier B.V 10.09.2014
Subjects
Online AccessGet full text
ISSN0378-5173
1873-3476
1873-3476
DOI10.1016/j.ijpharm.2014.06.026

Cover

More Information
Summary:[Display omitted] Spray drying is a valuable technique in pharmaceutical dosage formulation, capable of producing amorphous, spherical powders, suitable for pulmonary deposition and further downstream processing. In this study, we show that spray drying bacteriophages together with trehalose results in an amorphous powder matrix with high glass transition temperature (between 116 and 118°C), typical for amorphous trehalose. These powders are stable at low temperatures (4°C) and relative humidity (0%). However, high humidity causes crystallization of the amorphous matrix, destroying the embedded phages. Furthermore, storage at higher temperature (25°C) causes thermal instability of the embedded phages. The results show that storage conditions are important parameters to take into account in phage therapy development. The resulting particles are hollow spheres, with suitable aerodynamic diameters for deposition into the deep lungs. This opens possibilities to use these phage-containing powder formulations to tackle pulmonary infectious diseases, especially caused by antibiotic resistant pathogens.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0378-5173
1873-3476
1873-3476
DOI:10.1016/j.ijpharm.2014.06.026